The European Medicines Agency (EMA) has launched a survey of pharmaceutical companies to assess their preparedness for the United Kingdom’s upcoming withdrawal from the European Union, as it hopes to identify any concerns about the continued supply of drugs during the Brexit transition.
The European Medicines Agency (EMA) has launched a survey of pharmaceutical companies to assess their preparedness for the United Kingdom’s upcoming withdrawal from the European Union, as it hopes to identify any concerns about the continued supply of drugs during the Brexit transition.
The EMA is sending its survey directly to companies based in the United Kingdom that hold central EU marketing authorizations for medicines—as well as companies that have their quality control, batch release, import manufacturing sites, or pharmacovigilance operations in the United Kingdom—about their Brexit-related plans. Specifically, the EMA hopes to gain insight into companies’ plans to submit transfers, notifications, or variations to their marketing authorizations.
The EMA says that it hopes that the survey will identify companies in which “…there is a need for concerted action” to ensure the uninterrupted supply of medicines after Brexit and that it can help the EMA and the European Commission plan how to best use their resources in the days ahead. The survey, says the EMA, may also “…serve to stimulate those companies who have not yet taken any action” in planning for Brexit to begin developing and implementing plans.
Concerns about the availability of medicines in the United Kingdom and European Union following Brexit have intensified in recent months; despite recent assurances from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency that there will be no sudden overhauls to UK regulatory frameworks after Brexit, the continued lack of progress on a UK—EU trade deal raises the specter of potential drug shortages.
In November, the European Federation of Pharmaceutical Industries and Associations (EFPIA), an industry group, released the results of its own survey of 43 pharmaceutical companies and 33 national associations, which found that 45% of respondents expect trade delays in the event of a “no deal” Brexit. Currently, 45 million patient-ready packages of medicines are supplied to the European Union from the United Kingdom each month (and the United Kingdom receives 37 million packages each month from the European Union). Any trade delays, according to the EFPIA, could create significant issues for medicine availability.
Pharmaceutical companies will have until February 9 to complete the newly launched EMA survey, and the agency will share its findings and recommendations with the European Commission.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.